Flagship VentureLabs™ Introduces Symbiota, Pioneer of Agricultural Innovation Through the Plant Microbiome

Flagship VentureLabs™ Introduces Symbiota, Pioneer of Agricultural Innovation Through the Plant Microbiome

November 13, 2014

Symbiota Appoints Dr. Robert Berendes as Executive Chairman

Eleven Biotherapeutics Reports Third Quarter 2014 Financial Results

Eleven Biotherapeutics Reports Third Quarter 2014 Financial Results

November 13, 2014

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today reported financial results for the third quarter ended September 30, 2014 and recent business highlights.

Concert Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Update on CTP-354 Program

Concert Pharmaceuticals Reports Third Quarter 2014 Financial Results and Provides Update on CTP-354 Program

November 12, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc.

Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results

Agios Pharmaceuticals Reports Third Quarter 2014 Financial Results

November 7, 2014

 Data from Three Lead Clinical Stage Medicines to be Presented at Major Medical Meetings by end of 2014

Acceleron Pharma Reports Third Quarter 2014 Financial and Operational Results

Acceleron Pharma Reports Third Quarter 2014 Financial and Operational Results

November 7, 2014

 – Phase 2 data from beta-thalassemia and MDS trials selected for oral presentations at ASH –

– Phase 2 data from end-stage renal disease trial to be presented at ASN –

– Initiated final stage of beta-thalassemia and MDS phase 2 clinical trials –

– Innovative muscle drug now in human clinical trials –

 

Avedro Granted Korean Approval for its KXL® Cross-Linking System for Lasik Xtra®

Avedro Granted Korean Approval for its KXL® Cross-Linking System for Lasik Xtra®

November 7, 2014

Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that it has been granted approval from the South Korean Ministry of Food and Drug Safety (MFDS, formerly the KFDA) for the company’s KXL Cross-Linking System. The KXL System components include the VibeX family of riboflavin formulations. The KXL device is designed to perform Lasik Xtra and accelerated cross-linking for keratoconus and post-LASIK ectasia.

Syros Pharmaceuticals’ Scientists Publish New Method to Detect Epigenomic Changes Following Drug Treatment

Syros Pharmaceuticals’ Scientists Publish New Method to Detect Epigenomic Changes Following Drug Treatment

November 6, 2014

Paper in Cell Reports describes ChIP-Rx, a novel approach to measure how drugs alter gene control programs

BIND Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update

BIND Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update

November 6, 2014

- Significant pipeline progress in clinical development with BIND-014 to be reported at EORTC-NCI-AACR meeting and selection of BIND-510 as new product candidate using Accurin™ platform -

- Strengthened management and Board including Chief Medical Officer -

- Research and Development agreement with Merck provides access to two promising oncology candidates -

- Management to host conference call today at 8:30 a.m. EST -

BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology

BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin™ Nanomedicines for Oncology

November 6, 2014

Enables BIND to Develop Product Candidates Utilizing Merck Compounds

T2 Biosystems Reports 2014 Third Quarter Highlights and Financial Results

T2 Biosystems Reports 2014 Third Quarter Highlights and Financial Results

November 4, 2014

 IPO and First FDA Clearances Mark Beginning of Commercial Activity

LEXINGTON, Mass., Nov. 4, 2014 (GLOBE NEWSWIRE) -- T2 Biosystems (Nasdaq:TTOO) today reported operating highlights and financial results for the third quarter ended September 30, 2014. Highlights of the quarter included: